Based on the current knowledge of CA formation and clinical treatment, we designed a drug library for a proof-of-concept drug screening, including inhibitors of specific signaling pathways crucial for CA formation [8, 30–32] (Wnt/β-catenin, TGF-β/SMAD, JAK/STAT, and MAPK) and clinical drugs (metformin, berberine, and doxazosin). This evidence concerns the gene TGFB1 and cancer.